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OBJECTIVES The aim of this study was to evaluate the clinical, angiographic, and technical factors related
to successful stenting of diseased saphenous vein grafts (SVGs) using a novel filter-based
distal protection device.
BACKGROUND Protection of the distal microvasculature with a balloon occlusion and aspiration system has
been shown to reduce atherothrombotic embolization and peri-procedural myocardial
infarction (MI) after percutaneous coronary intervention (PCI) in SVGs. The safety, efficacy,
and technical factors relating to procedural success with filter-based distal protection devices
are unknown.
METHODS Percutaneous coronary intervention was performed in 60 lesions in 48 patients undergoing
SVG intervention with the FilterWire EX distal protection system in a phase I experience at
six sites. A larger phase II study was then performed in 248 lesions in 230 SVGs at 65 U.S.
centers.
RESULTS Cumulative adverse events to 30 days occurred in 21.3% of patients in phase I, including a
19.1% rate of MI. Numerous anatomic, device-specific, and operator-related contributors to
these adverse events were identified, resulting in significant changes to the protocol and
instructions for use. Subsequently, despite similar clinical and angiographic characteristics to
the phase I patients, the 30-day adverse event rate in phase II was reduced to 11.3% (p 
0.09), due primarily to a lower incidence of peri-procedural Q-wave and non–Q-wave MI.
CONCLUSIONS Distal protection during SVG PCI with the FilterWire EX is associated with a low rate of
peri-procedural adverse events compared to historical controls. A unique set of anatomic,
technical, and operator-related issues exist with distal filters which, if ignored, may reduce
their effectiveness. (J Am Coll Cardiol 2002;40:1882–8i) © 2002 by the American College
of Cardiology Foundation
Embolization of atherothrombotic debris after percutaneous
coronary intervention (PCI) in diseased saphenous vein
grafts (SVGs) results in peri-procedural myocardial infarc-
tion (MI) in as many as one-third of patients (1–4). Of
numerous investigated approaches (5–11), only protection
of the distal microcirculation by a balloon occlusion and
aspiration system (the PercuSurge GuardWire) has been
clearly demonstrated to enhance the safety of contemporary
SVG intervention (12).
Catheter-based filters as an adjunct to SVG intervention
have recently entered clinical investigation (13–15). Char-
acterized by their relative ease of use and maintenance of
perfusion, distal filters may at first seem inherently prefer-
able to balloon occlusion and aspiration systems. However,
the safety and efficacy of distal filters have not yet been
demonstrated. Therefore, we performed two consecutive
prospective, multicenter registries with a new distal protec-
tion device, the FilterWire EX (Embolic Protection Inc.,
Boston Scientific Corp., Natick, Massachusetts), to examine
its effectiveness during PCI of SVGs, and to uncover
technical and device related factors impacting procedural
success.
METHODS
Before initiation of the pivotal U.S. randomized trial for
device approval, the FilterWire EX was evaluated in a phase
I study at six sites. After review of the phase I 30-day data,
the multicenter pivotal phase II study commenced with a
lead-in stage at 65 centers enrolling up to five patients per
site. Both studies were performed under a Food and Drug
Administration (FDA) investigational device exemption.
The studies were approved by the investigational review
board at each participating institution, and all patients
signed written, informed consent before study entry.
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Study device. The FilterWire EX consists of a distal
polyurethane filter with 80 to 110 m diameter pores
mounted on a 0.014-inch steerable guidewire via a “spinner
tube” which permits independent 360° wire rotation and
steering (Fig. 1). The filter is attached to a self-expandable
radiopaque nitinol loop which is elliptical in shape, afford-
ing maximal surface area for particle capture and compati-
bility with vessels 3.5 to 5.5 mm in diameter with the same
device. The collapsed filter (3.9F crossing profile) is passed
distal to the lesion and deployed by retracting the delivery
sheath. The filter is then closed with the delivery/retrieval
sheath after PCI and withdrawn.
Phase I study—Patient entry criteria. Consecutive pa-
tients with 1 eligible SVG lesions meeting the following
inclusion criteria were enrolled: age21 years; lesion length
40 mm, reference vessel diameter 3.5 to 5.5 mm, diameter
stenosis 100% and Thrombolysis In Myocardial Infarc-
tion (TIMI) flow grade 2; and presence of 2 cm of
straight segment in the SVG distal to the lesion. Major
exclusion criteria included: MI within 24 h or CK-MB
2 normal; contrast or study medication contraindica-
tion; treatment required in non-qualifying vessels; left
ventricular ejection fraction 30%; and planned treatment
with atherectomy, thrombectomy, laser or other distal
protection devices.
Phase I study—Study procedures. All patients received
aspirin before the procedure and indefinitely thereafter.
Clopidogrel (or ticlopidine) was recommended before the
procedure and continued for 30 days after stent placement.
An activated clotting time of 300 s was achieved before
PCI, or 200 to 300 s if glycoprotein (GP) IIb/IIIa inhibitors
were administered (per investigator discretion). Percutane-
ous coronary intervention was then performed with Filter-
Wire distal protection. CK-MB levels were measured at
baseline and every 8 h 3 post procedure. Clinical
follow-up occurred at 30 days.
Phase I failure analysis. Given a higher than expected
adverse event rate in phase I, a detailed failure analysis was
performed, including procedural technique and angio-
graphic review. As described in the Results, four correctable
technical errors were identified that appeared causally re-
lated to major adverse cardiac events (MACE). These
technical issues were addressed in the phase II protocol and
received repeated emphasis at a series of investigator meet-
ings and study conferences.
Phase II study protocol and procedures. Compared with
phase I, the phase II entry criteria allowed inclusion of more
complex lesions, including vessels with TIMI-1 flow, and
lesions of any length. Otherwise the phase I and II enroll-
ment criteria were similar. The phase II protocol incorpo-
rated five important changes in technique and operator
instructions: 1) a2.5-cm gap before the distal anastomosis
was required for placement of the filter apparatus distal to
the lesion; 2) the FilterWire loop was required to be placed
in the mid portion of a 2-cm straight section of the SVG
to avoid deformation of the device (Fig. 2); 3) orthogonal
views were mandated to document appropriate filter appo-
sition before dilation; 4) specific instructions were provided
not to retract the entire debris-laden filter into the sheath;
and 5) the importance of established distal protection
during all SVG dilations was emphasized.
End points and definitions. Study end points and defini-
tions were identical for both registries. The primary end
point was the incidence of MACE at 30 days, defined as
Abbreviations and Acronyms
GP  glycoprotein
LVEF  left ventricular ejection fraction
MACE major adverse cardiac events
MI  myocardial infarction
PCI  percutaneous coronary intervention
SVG  saphenous vein graft
TIMI  Thrombolysis In Myocardial Infarction
TLR  target lesion revascularization
Figure 1. The FilterWire EX, consisting of a 0.014-inch steerable guide-
wire on which a freely rotating distal polyurethane filter is mounted, shown
in its deployed configuration (top and middle) and retracted position
(bottom) after being withdrawn into the delivery/retrieval sheath (white
arrow). A distal nosecone (black arrow) prevents passage of the sheath
beyond the wire tip
Figure 2. Diagrammatic representation of the FilterWire across a vein
graft lesion, with the minimal distances pre-specified in the phase II
protocol for optimal performance.
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death, MI, or target lesion revascularization. Myocardial
infarction was defined as any postprocedural CK-MB 3
normal.
Data collection, quality assurance, and statistical analysis.
Data were independently monitored on-site for accuracy,
and double-key entered into a computerized database by an
independent research organization. An independent Clini-
cal Events Committee adjudicated all adverse outcomes.
Quality control measures included use of independent
angiographic and electrocardiographic core laboratories.
These processes and the organizations employed were iden-
tical for both studies.
Categorical variables were compared by chi-squared anal-
ysis or Fisher exact test. Continuous variables are presented
as mean  standard deviation and were compared by
unpaired Student t test. All p values are two-tailed. Signif-
icance was determined at the p  0.05 level. The indepen-
dent determinants of 30-day MACE in the phase II cohort
were determined by entering all variables predictive of
adverse outcomes by univariate analysis with a p value
0.10 into a multivariate logistic regression model.
RESULTS
Phase I and phase II patient populations. Between Oc-
tober 2000 and April 2001, 48 consecutive patients under-
went intervention of 60 SVG lesions with FilterWire distal
protection in the phase I study. Subsequently, between May
2001 and April 2002, 230 consecutive patients underwent
intervention of 248 SVG lesions with FilterWire distal
protection during the roll-in period of the phase II study.
The baseline demographic and lesion characteristics of the
two study cohorts were similar, except hypertension was
more common in phase I, patients in phase II were more
Table 1. Baseline Clinical and Angiographic Characteristics of Patients Enrolled in the Phase I
and Phase II Registry Studies
Phase I Phase II p Value
Clinical features
N patients 48 230 —
Age (yrs) 69.9  9.2 69.5  9.7 0.79
Gender (male) 78.7% 82.7% 0.53
Hypertension 93.6% 77.0% 0.01
Hyperlipidemia 78.7% 88.3% 0.10
Diabetes mellitus 44.7% 35.0% 0.24
Cigarette smoking within past year 4.3% 16.1% 0.04
Prior stroke or transient ischemic attack 10.6% 18.3% 0.28
Prior MI 66.7% 62.0% 0.61
Angina class
1 6.7% 4.3% 0.45
2 6.7% 19.6% 0.06
3 44.4% 35.9% 0.31
4 42.2% 40.2% 0.87
Graft age (yrs) 10.4  5.8 11.0  5.3 0.40
Target vessel
SVG to LAD 26.3% 19.6% 0.27
SVG to LCX 33.3% 40.2% 0.44
SVG to RCA 40.4% 40.2% 0.99
LVEF 47%  11% 49%  12% 0.03
Quantitative coronary angiography (core lab)
N lesions 60 248
Thrombus present 64.9% 65.3% 0.98
Eccentricity 42.1% 55.3% 0.10
Ulceration 24.6% 20.1% 0.47
Calcification 8.8% 8.5% 0.96
Angulation (45°) 0% 3.5% 0.39
Type B2/C lesions 89.5% 81.4% 0.44
Reference vessel diameter pre (mm) 3.55  0.6 3.46  0.7 0.38
Minimal luminal diameter pre (mm) 1.22  0.6 1.26  0.5 0.61
Diameter stenosis pre (%) 66  13 63  14 0.20
Lesion length pre (mm) 15.5  10.2 13.9  9.1 0.24
TIMI flow pre
0/1 7.0% 2.5% 0.36
2 7.0% 14.1% 0.18
3 86.0% 83.4% 0.84
LAD  left anterior descending artery; LCX  left circumflex artery; LVEF  left ventricular ejection fraction; MI 
myocardial infarction; RCA  right coronary artery; SVG  saphenous vein graft; TIMI flow  Thrombolysis In Myocardial
Infarction flow grade.
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likely to be active smokers, and left ventricular function was
slightly better in phase II (Table 1).
Results of phase I. The FilterWire was successfully deliv-
ered and deployed in 95.7% of cases. Postprocedural
TIMI-3 flow was present in 94.7% of grafts, TIMI-2 flow
in 3.5%, and TIMI-0/1 flow in 1.8%. In-hospital MACE
occurred in 18.8% of patients prior to hospital discharge,
and in 21.3% of patients by 30 days. As shown in Table 2,
most events consisted of peri-procedural MI.
Failure analysis. Detailed procedural and angiographic
analysis of the 10 cases in which MACE occurred revealed
the following possible causative factors (several of which
were present in some patients): wire bias or geometric
factors resulting in filter loop malapposition (Fig. 3), n  3;
excessively distal lesion location such that the filter could
not open properly or was placed in a native coronary vessel,
leaving proximal branches unprotected (Fig. 4), n  4;
balloon dilations and/or stent implantations performed
without distal protection (excluding pre-dilation), n  4;
SVG diameter 7 mm with resultant filter malapposition,
n  1; filter placed in a single distal limb of a bifurcating Y
graft, such that the other limb was unprotected, n  1; and
heavily loaded filter completely retracted into the delivery
sheath, resulting in atheromatous extrusion and emboliza-
tion, n  1.
Results of phase II. The FilterWire was successfully de-
livered and deployed in 96.5% of cases. Stent use, implan-
tation parameters, and procedural outcomes were similar to
phase I, except that GP IIb/IIIa inhibitors were used more
frequently (Table 3). Angiographic complications, as deter-
mined by the core laboratory, were less frequent in phase II
compared with phase I, with fewer episodes of no reflow
and distal thromboemboli noted. Moreover, 30-day cumu-
lative MACE occurred in fewer patients in phase II than in
phase I, predominantly because of a lower rate of peri-
procedural MI (Fig. 5). From 18 baseline variables, the only
univariate correlates of 30-day MACE in patients under-
going SVG intervention with FilterWire distal protection
were longer lesion length, greater diameter stenosis, and the
presence of thrombus (Table 4); by multivariate analysis,
only long lesion length was independently predictive of
MACE (odds ratio  3.69, p  0.015).
DISCUSSION
The present report details a large multicenter experience
with FilterWire distal protection as an adjunct to PCI in
308 lesions in 278 SVGs. Use of this device resulted in
30-day rates of MACE below that expected from historical
controls. Moreover, during the course of this sequential
two-phase investigation, a unique set of anatomic, technical,
and operator-related issues were uncovered which, if ig-
nored, may reduce the effectiveness of the FilterWire.
Phase I results and failure analysis. A disturbingly high
21.3% 30-day event rate occurred in the first 60 lesions in
Table 2. 30-Day Adverse Cardiac Events in 48 Patients
Undergoing SVG Intervention of 60 Lesions With FilterWire
Distal Protection in the Phase I Registry
Death 2.1%
MI 19.2%
Q-wave MI 2.1%
non–Q-wave MI 17.1%
TLR 0%
Any major adverse cardiac event 21.3%
MI  myocardial infarction; SVG  saphenous vein grafts; TLR  target lesion
revascularization.
Figure 3. Potential failure mode—lack of filter apposition against the vessel wall. (A) Post-stenting of the mid shaft of the saphenous vein graft to the right
coronary artery (black arrow) with the FilterWire in place (white arrow). (B) Magnification of panel A—the nitinol loop of the FilterWire may be seen.
(C) Further magnification and enhancement of the FilterWire, showing that the nitinol loop (black arrow) and collection filter (cross hatched net) are
clearly lifted off the inferior wall of the vein graft, likely due to geometric wire bias resulting from placement of the distal wire tip in the posterolateral branch
(white arrow). Relocating the guidewire tip into the more inferior posterior descending artery may have apposed the filter loop against the vein graft wall.
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48 SVGs, similar to that expected from historical controls.
A detailed failure analysis revealed several correctable con-
ditions that may have contributed to adverse events. Several
of these issues were intuitive (performance of dilation
without protection in place), whereas others were clearly
operator- or device-specific.
First, several cases of distal embolization were temporally
related to balloon dilation without the protection device in
place. Typically the device had been removed after an
apparently successful result, following which residual disease
or dissection were noted requiring further intervention,
which was performed without protection either because of
Figure 4. Potential failure mode—excessively distal lesion resulting in incomplete filter opening or unprotected native side branches. (A) Ulcerated lesion
(arrow) in the distal shaft of the saphenous vein graft to the obtuse marginal branch of the left circumflex artery. (B) FilterWire deployed, with the distal
nitinol loop protruding into the upper branch of the bifurcating obtuse marginal (arrow). (C) As a result, the polyurethane collection filter (arrow and cross
hatched net) cannot open fully and is compressed in the undersized branch (3.0 cm), impairing particulate recovery both in the partially protected superior
branch and unprotected inferior branch.
Table 3. Procedural Results, Comparing Patients Enrolled in Phase I and Phase II
Phase I Phase II p Value
N patients 48 230 —
N lesions 60 248 —
Lesions stented 96.7% 96.6% 0.99
N stents per patient 1.24  0.4 1.16  0.4 0.25
Total stent length (mm) 25.2  13.1 22.2  12.0 0.09
Maximum stent diameter (mm) 4.03  1.3 4.13  0.6 0.44
Maximum implantation pressure (atm) 13.8  1.9 14.7  4.1 0.11
Glycoprotein IIb/IIIa inhibitor use 29.8% 52.2% 0.01
No reflow 12.3% 5.0% 0.07
Visible distal thromboemboli 10.5% 3.0% 0.03
Abrupt closure 5.3% 2.5% 0.38
Quantitative coronary angiography (core lab)
Reference vessel diameter post (mm) 3.60  0.6 3.48  0.7 0.24
In-lesion minimal luminal diameter post (mm) 3.07  0.7 3.00  0.7 0.51
In-lesion diameter stenosis post (%) 15%  15% 13%  12% 0.47
TIMI flow post
0/1 1.7% 2.0% 0.97
2 3.4% 3.5% 0.99
3 94.9% 94.5% 0.93
TIMI flow  Thrombolysis In Myocardial Infarction flow grade.
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difficulty in recrossing the treated zone or perceived low
embolic potential. These cases reinforce the difficulty in
predicting embolic risk during SVG intervention and em-
phasize the need for distal protection during all phases of
the procedure. Similarly, placing the filter distal to a
side-to-side Y-graft anastomosis will clearly allow emboli in
the unprotected proximal branch.
A second and unexpected correlate of peri-procedural MI
was the lack of optimal filter apposition against the SVG
wall. Because even a freshly placed filter offers a modest flow
barrier, blood perfusate containing embolic particles will
take the path of least resistance, selectively shunting debris
around the filter when possible. The most common cause of
lack of filter apposition was lifting of the nitinol wire frame
off the vessel wall due to wire bias from anatomic and
geometric factors. Notably, this condition may be hidden
when the filter is viewed en face, only to be revealed by
observing the filter loop on edge in an orthogonal projec-
tion. This condition may at times be corrected by moving
the filter apparatus to a straighter portion of the vessel, or
redirecting the distal guidewire into another branch (Fig. 3).
Moreover, as the unrestrained diameter of the nitinol loop is
6 mm, positioning the distal apparatus in an oversized
segment will by definition also result in malapposition.
A third cause of MACE was overestimation of the
distance from the lesion to the distal anastomosis, resulting
in the collection net being released in a native arterial
branch, with either subsequent narrowing of the collection
aperture or lack of protection of secondary branches.
Phase II results. As a response to this analysis, the phase II
protocol and Instructions for Use were modified, and an
intense education campaign was initiated for all sites,
consisting of investigator meetings, written communica-
tions, and teleconferences. Orthogonal views were man-
dated to detect filter loop malapposition; the distance
required from the lesion to the distal anastomosis was
increased; a straight section for the distal apparatus was
required; instructions were given to retract the filter into the
retrieval sheath just enough to close the nitinol loop; and the
importance of established distal protection during all phases
of the intervention was emphasized. In the large phase II
experience consisting of SVG intervention in 248 lesions in
230 vessels at 65 sites, the MACE rate was reduced to
11.3%, approximately 50% lower than in phase I (despite
nearly identical patient and vein graft characteristics), due
largely to reductions in Q-wave and non–Q-wave MI.
These improved results are especially notable given the
greater number of sites with less experience in phase II,
representing a real-world example of how early lessons
learned may be effectively communicated to future opera-
tors.
An additional observation that deserves mention pertains
to GP IIb/IIIa inhibitor use, which by operator choice was
more common in phase II than phase I. Although
Figure 5. Cumulative 30-day major adverse cardiac event (MACE) rates in 48 patients in the phase I study compared to 230 patients in the phase II study.
MI  myocardial infarction; TLR  target lesion revascularization.
Table 4. Variables Correlating With MACE Within 30 Days
Patient Characteristic
% MACE
With Variable
Present
% MACE
With Variable
Absent
p
Value
Age  70 yrs 10.3% 13.0% 0.68
Male gender 11.2% 12.8% 0.78
Hypertension 10.3% 15.4% 0.33
Diabetes 6.3% 14.3% 0.08
History of MI 12.4% 10.7% 0.83
Renal insufficiency 12.5% 11.3% 0.77
SVG age 10 yrs 11.7% 12.5% 0.91
LVEF  median 9.4% 12.2% 0.66
Reference vessel diameter
 median
13.6% 10.8% 0.65
Minimal lumen diameter
 median
11.2% 13.0% 0.82
Diameter stenosis
 median
17.8% 6.6% 0.02
Lesion length  median 18.2% 5.7% 0.02
Baseline TIMI flow 3 18.8% 10.7% 0.23
Thrombus present 15.8% 4.9% 0.05
Eccentric lesion 12.5% 11.7% 0.95
Angulated lesion (45°) 14.3% 12.1% 0.92
IIb/IIIa inhibitor used 13.3% 9.1% 0.31
LVEF  left ventricular ejection fraction; MACE  major adverse cardiac events;
MI  myocardial infarction; SVG  saphenous vein graft; TIMI flow  Throm-
bolysis In Myocardial Infarction flow grade.
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GP IIb/IIIa inhibitors have not been found to be beneficial
as an adjunct to PCI in SVGs (6), it is conceivable that by
reducing platelet-fibrin deposition on the filter surface, GP
IIb/IIIa inhibitors might diminish the slow flow state that
can occur when filters become overloaded, a phenomenon
which has been related to MACE.
Other causes of MACE and device enhancements.
Despite the improved outcomes in phase II, the fact that
10% of patients still developed peri-procedural MI in phase
II suggests that other device- and operator-related variables
may still result in MACE and highlights the need for future
device enhancements. The MACE rates were increased
approximately three-fold with long lesions, high-grade
baseline stenoses, and in the presence of thrombus, empha-
sizing that particular care is warranted when intervening in
SVGs with these characteristics, even with filter-based
distal protection. Macroscopic or angiographically unappar-
ent distal thromboemboli may be induced by guidewire or
device crossing of high-grade friable lesions, suggesting that
outcomes might be improved by more steerable, flexible,
and lower profile catheters. Debris collection may be in-
complete as smaller particles may pass through the filter
pores, and an excessively burdened filter may pose chal-
lenges for loop closure and debris retrieval without material
extrusion. Future FilterWire iterations will incorporate a
self-centering mechanism to reduce the impact of geometric
influences and a crossing profile below 3F.
Comparison with alternative methods for distal protec-
tion. The results of this investigation apply only to the
FilterWire EX; other distal protection filter systems may
have unique advantages or disadvantages which might result
in a very different safety or efficacy profile. Similarly, the
results of this study should not be used to support mean-
ingful comparisons between the investigational FilterWire
and balloon occlusion and aspiration with the FDA-
approved PercuSurge GuardWire. However, on the basis of
these phase II outcomes, a non-inferiority trial has been
initiated in which 650 patients undergoing PCI in SVGs
were randomized to distal protection with the FilterWire
versus the GuardWire; the results of this study are expected
in late 2002.
Clinical implications. The FilterWire, while currently in-
vestigational in the U.S., is widely used in many parts of the
world, and thus the results of this investigation have
immediate clinical implications for the operators using this
device. Recognition of the unique set of anatomic, technical,
and operator-related issues that exist with the FilterWire
(and indeed with all distal protection devices), as described
herein, may further improve the outcomes for high-risk
patients undergoing PCI in degenerated SVGs with distal
protection.
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APPENDIX
Phase I study organization: Principal investigator (PI):
Gregg W. Stone. Clinical sites and local PIs: Lenox Hill
Hospital, New York, NY, Gregg W. Stone (PI); Ochsner
Clinic, New Orleans, LA, Steve Ramee (PI), Chris White;
Brigham & Women’s Hospital, Boston, MA, Campbell
Rogers (PI); William Beaumont Hospital, Royal Oak, MI,
Steve Almany (PI); Western Pennsylvania Hospital, Pitts-
burgh, PA, John George (PI); University of Texas San
Antonio, San Antonio, TX, Steve Bailey (PI).
Phase II study organization: Executive Committee: Gregg
W. Stone (PI), Campbell Rogers (Co-PI), Steve Ramee,
Richard E. Kuntz, Milton McColl. Clinical sites and local
PIs: Kaiser Permanente, Los Angeles, CA, Vicken Aharo-
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nian (PI); Palmetto Richland Memorial Hospital, Colum-
bia, SC, Milton Alexander (PI); Beaumont Hospital, Royal
Oak, MI, Steven L. Almany (PI); University Hospital, San
Antonio, TX, Steven Bailey (PI); Laval Hospital, Quebec,
Canada, Gerald Barbeau (PI); St. Joseph Mercy Hospital,
Ann Arbor, MI, Jim Bengtson (PI); Moses Cone Hospital,
Greensboro, NC, Bruce Brodie (PI); Scripps Memorial
Hospital, La Jolla, CA, Maurice Buchbinder (PI); Morton
Plant Mease, Clearwater, FL, Patrick A. Cambier (PI); St.
Joseph’s Hospital Health, Syracuse, NY, Ron Caputo (PI);
Deborah Heart and Lung, Browns Mills, NJ, Se Do Cha
(PI); Sacred Heart Medical Center, Eugene, OR, Joseph
W. Chambers (PI); Medical College of Ohio, Toledo, OH,
Christopher Cooper (PI); Presbyterian Healthcare, Char-
lotte, NC, Dave Cox (PI); Sarasota Memorial Hospital,
Sarasota, FL, Stephen C. Culp (PI); University of Wash-
ington, Seattle, WA, Larry S. Dean (PI); Albany Medical
Center, Albany, NY, Augustin DeLago (PI); Arizona Heart
Institute, Phoenix, AZ, Walid Alami (PI), Nabil Dib (PI);
Munroe Regional Medical, Ocala, FL, Robert Feldman
(PI); Western Baptist Hospital, Paducah, KY, J. Kenneth
Ford (PI); Beth Israel Medical Center, New York, NY,
John Fox (PI); St. Thomas Hospital, Nashville, TN, Joseph
L. Fredi & P. Robert Myers (PI); Mount Sinai Medical
Center, Miami Beach, FL, Francesca Gallarello (PI); St.
Mary’s Hospital, Rochester, MN, Kirk N. Garratt (PI);
Western Pennsylvania Hospital, Pittsburgh, PA, John
George (PI); Carolinas Healthcare, Charlotte, NC, Robert
H. Haber (PI); Providence Hospital, Columbia, SC, Patrick
A. X. Hall (PI); Vancouver Hospital, Vancouver, BC,
Canada, Jaap Hamburger (PI); St. Vincent Hospital, Indi-
anapolis, IN, James B. Hermiller (PI); Presbyterian Health-
care, Philadelphia, PA, Howard Herrmann (PI); St. Luke’s
Medical Center, Phoenix, AZ, Richard R. Heuser (PI);
New York Presbyterian, New York, NY, Mun K. Hong
(PI); VA Puget Sound Health Care, Seattle, WA, Samir
Kapadia (PI); VA Palo Alto, Palo Alto, CA, Aaron Kaplan
(PI); Long Island Jewish Hospital, New Hyde Park, NY,
Barry Kaplan (PI); North Shore University Hospital at
Manhasset, Manhasset, NY, Stanley Katz (PI); Maine
Medical Center, Portland, ME, Mirle A. Kellett (PI); The
Christ Hospital, Cincinnati, OH, Dean J. Kereiakes (PI);
University of Oklahoma Hospital, Oklahoma City, OK,
George Khammar (PI); Eisenhower Medical Center, Ran-
cho Mirage, CA, Puneet K. Khanna (PI); Mount Sinai
Hospital, Chicago, IL, Sandeep Khosla (PI); St. Joseph’s
Hospital of Atlanta, Atlanta, GA, William Knopf (PI);
Duke University Medical Center, Durham, NC, David F.
Kong (PI); Our Lady of Lourdes Medical Center, Camden,
NJ, Richard Kovach (PI); Henry Ford Hospital, Detroit,
MI, Aaron Kugelmass (PI); University of Ottawa Heart,
Ottawa, Ontario, Canada, Marino Labinaz (PI); Barnes
Jewish Hospital, St. Louis, MO, John LaSala (PI); VAMC/
Baylor College of Medicine, Houston, TX, Glenn N.
Levine (PI); The Dayton Heart Hospital, Dayton, OH,
Sudhakar Maraboyina (PI); Buffalo General Hospital, Buf-
falo, NY, A. R. Zaki Masud (PI); Good Samaritan Hospi-
tal, Los Angeles, CA, Ray Matthews (PI); Hahnemann
University, Philadelphia, PA, Daniel McCormick (PI);
Greenville Memorial Hospital/St. Francis Hospital, Green-
ville, SC, Brent McLaurin (PI); St. Joseph’s Hospital,
Marshfield, WI, Juan Mesa (PI); St. John’s Hospital/
Memorial Medical Center, Springfield, IL, Gregory Mish-
kel (PI); St. Luke’s Episcopal Hospital, Houston, TX, Ali
Mortazavi (PI); Arkansas Heart Hospital, Little Rock, AR,
Bruce E. Murphy (PI); Fountain Valley Regional Hospital,
Fountain Valley, CA, Subbarao Myla (PI); Hoag Memorial
Hospital, Newport Beach, CA, Subbarao Myla (PI); Chris-
tiana Care, Newark, DE, James Ritter (PI); Sacramento
Heart/Sutter Medical Center, Sacramento, CA, David K.
Roberts (PI); Brigham and Women’s Hospital, Boston,
MA, Campbell Rogers (PI); Phoenix Memorial Hospital,
Phoenix, AZ, Robert M. Siegel (PI); University of Arizona/
Sarver Heart Center, Tucson, AZ, Marvin J. Slepian (PI);
Lenox Hill Hospital, New York, NY, Gregg Stone (PI);
The Valley Hospital, Ridgewood, NJ, Janet Strain (PI);
Mercy Medical Center, Des Moines, IA, Mark Tannen-
baum (PI); Queen Elizabeth Health Sciences Centre, Hali-
fax, NS, Canada, Robert Teskey and Hussein Beydoun (PI);
Washington Adventist Hospital, Takoma Park, MD, Mark
A. Turco (PI); St. Paul’s Hospital, Vancouver, BC, Canada,
John Webb (PI); Ochsner Foundation Clinic, New Orleans,
LA, Chris White (PI); St. Luke’s Roosevelt Hospital, New
York, NY, James Wilentz (PI); Spectrum Health, Grand
Rapids, MI, Kevin Wolschleger (PI); Stanford Hospital,
Stanford, CA, Alan Yeung (PI).
Common phase I and II study organization: Data Man-
agement, Clinical Events Adjudication, and Biostatistical
Analysis: Harvard Clinical Research Institute, Cardiovascu-
lar Data Analysis Center, Boston, MA, Richard E. Kuntz
(Director). Data Monitoring: Boston Scientific Corp,
Natick, MA. Core Angiographic Laboratory: Brigham and
Women’s Hospital Core Angiographic Laboratory, Boston,
MA, Jeffrey J. Popma (Director). Electrocardiographic Core
Laboratory: Cardiovascular Data Analysis Center, Boston,
MA, Peter Zimetbaum (Director).
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